Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sacubitril Alone? A Statistician's Proposal

Executive Summary

FDA reviewer urged rejection of Novartis' Entresto because NDA did not meet combo reg, but offered alternative scenario: approve the novel component, sacubitril, alone for circumscribed indication in heart failure.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register